$PFE

DAMICO JENNIFER B. sold $83K of PFE

DAMICO JENNIFER B. (SVP & Controller) sold 3,278 shares of PFIZER INC (PFE) at $25.40 on 2026-08-05.

Original reporting
SEC EDGAR · DAMICO JENNIFER B.
Published Aug 6, 2026, 3:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 3:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFE
Neutral
high confidence
Mentioned
$PFE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

Traders may note insider selling as a sentiment datapoint, but the disclosure lacks any fundamental trigger (no earnings, guidance, deal, or regulatory update).

02

Market read

A routine insider open-market sale is disclosed; it is unlikely to change the investment thesis absent other catalysts.

03

What to watch

The article provides only the sale details, not motivations, tax events, or whether other insiders executed offsetting buys.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-06, transaction dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for Pfizer.

Company-level read

Ticker impact

$PFENeutralHigh confidence
Context

Pfizer Form 4 shows SVP & Controller Jennifer B. Damico sold 3,278 shares at $25.40 on 2026-08-05, totaling $83,261.20.

Expected impact

Likely minimal near-term impact on PFE price; treat as low-signal insider activity.

Evidence & confidence

The filing discloses a single officer sale size and price, without any accompanying corporate event, guidance change, or regulatory action.

Market effects

No clear read-through to pharma sector fundamentals from a single officer sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; absence of a 10b5-1 plan does not automatically imply negative information.

Key entities

  • Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • Jennifer B. Damico

    SVP & Controller who sold 3,278 shares at $25.40 on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFEHighAI 8/10

International Business: Pfizer net profit up

Pfizer raised its full-year revenue forecast to $62-64bn and earnings to $2.95-$3.05 per share, citing strong demand for drugs like Padcev and Eliquis. CEO Albert Bourla attributed the increase to Q3 performance and confidence in the company's strategy. The company has invested heavily in acquisitions, including Seagen and Metsera, to drive growth. Analysts note that long-term success depends on experimental treatments in development.

$PFEHighAI 9/10

Pfizer Inc. Q3 2026 Earnings Call Summary

Pfizer reported Q3 2026 earnings, highlighting 32% growth in launched and acquired products, including Seagen and Biohaven. The company raised full-year revenue guidance to $62-64B. Management projects high single-digit revenue CAGR from 2028-2033, driven by a strong pipeline. Pfizer also announced a $650M charge related to the Innovent transaction and aims for $2.5B in additional cost savings by 2029.

$PFEHighAI 8/10

Pfizer (PFE) Q3 2026 Earnings Call Transcript

Pfizer (PFE) reported Q3 2026 revenue of $617 billion, up 7% operationally excluding COVID-19 products. Key growth drivers included Padcev, NURTEC, and Lorbrena. The company raised full-year revenue and EPS guidance, citing strong performance and pipeline progress. Pfizer also announced additional cost-saving initiatives. According to the company, strategic acquisitions and R&D investments are driving growth, with plans for multiple Phase 3 trials in 2026 and potential approvals in 2028.

$PFEMed

Pfizer, fresh to China’s obesity market, looks to Viagra model to compete

Pfizer, partnering with Sciwind Biosciences, has launched Ecnoglutide, an obesity drug, in China. Pfizer CEO Albert Bourla compared the strategy to Viagra's success, noting the potential for out-of-pocket consumer purchases. The drug was acquired for $495 million, with Pfizer aiming to leverage its experience in self-pay markets. Pfizer also plans global expansion, focusing on berobenatide and other pipeline assets.